Higher concentrations of fractalkine were, however, associated with higher titers of anti-MBP antibodies (r = 0.413, P = 0.021) (Figure 4c) and increased brain atrophy (r = 0.879, P = 0.004) (Figure 4d). Here, CX3CL1 is linked to Brain atrophy.